Bria-OTS+™ Platform
Multiple Cancers (Breast, Prostate, Lung, Melanoma)
Preclinical/Phase 1Planned
Key Facts
Indication
Multiple Cancers (Breast, Prostate, Lung, Melanoma)
Phase
Preclinical/Phase 1
Status
Planned
Company
About BriaCell Therapeutics
BriaCell Therapeutics is a clinical-stage biotech focused on developing targeted cellular immunotherapies to transform cancer care. Its core strategy is advancing Bria-IMT™, a Fast Track-designated candidate in a pivotal Phase 3 study for metastatic breast cancer, while expanding its pipeline through the innovative Bria-OTS™ platform, which enables personalized, off-the-shelf treatments. The company has demonstrated promising clinical data, including extended survival in heavily pre-treated patients, and is backed by collaborations with the National Cancer Institute.
View full company profile